Hormonoterapia del cáncer de próstata. Farmacología clínica

Estévez Carrizo, Francisco E.
Rev. méd. Urug ; 17: 10-6, abr. 2001. tab
Artículo en Español | BVSNACUY | ID: bnu-11223

Documentos relacionados

  1. Synthesis and characterization of two potential impurities (des-ethyl-Ganirelix) generated in the Ganirelix manufacturing process.
  2. Evaluation of effects of temperature and humidity on the secondary structure of Ganirelix in an injectable formulation and comparison with Orgalutran® using circular dichroism spectroscopy.
  3. Single or repeated immunization against GnRH fails to completely abolish spermatogenesis in dwarf bucks (Capra hircus).
  4. Ovulation and birth after administration of progesterone trigger-two case reports.
  5. Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists.
  6. Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study.
  7. Girls with idiopathic central precocious puberty did not display substatial changes in body mass index after treatment with gonadotropin-releasing hormone analogues.
  8. GnRH-Agonist Ovulation Trigger in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF with Stop GnRH-Agonist Combined with Multidose GnRH-Antagonist Protocol.
  9. The effect of luteinizing hormone changes in GnRH antagonist protocol on the outcome of controlled ovarian hyperstimulation and embryo transfer.
  10. Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial.